Anupam Rasayan buys 74.20% stake in Bliss GVS Pharma
The specialty chemicals firm is entering the pharmaceutical sector by acquiring a controlling stake in the listed drugmaker.
— 2 earlier stories on Anupam Rasayan India Ltd. →What's new
- Anupam Rasayan board approved the acquisition of up to 74.20% of Bliss GVS Pharma.
- The deal marks the company's entry into the pharmaceutical industry.
- Financial terms of the acquisition remain undisclosed.
Why this matters
This move shifts Anupam Rasayan from its core specialty chemicals business into the pharmaceutical sector. Gaining control of a separate listed entity suggests a major change in capital allocation and corporate structure.
What we're watching
- The total cash outlay required for the acquisition.
- How the company plans to integrate Bliss GVS Pharma into its existing operations.
- Regulatory approvals required to finalize the change in control.
The full read
Anupam Rasayan is moving into the pharmaceutical sector. The company's board approved the acquisition of up to 74.20% of Bliss GVS Pharma, a listed drugmaker. This is a departure from its core specialty chemicals and custom synthesis business. The deal provides Anupam Rasayan with a controlling stake in a separate listed entity, which will likely lead to the consolidation of the target's financials. While the company has not disclosed the financial terms, the scale of the acquisition makes it a material event for shareholders. The next test is the disclosure of the purchase price and the integration plan for the new business unit. For now, the move represents a significant shift in the company's strategic direction.
Questions answered
- What is the primary objective of this acquisition?
- Anupam Rasayan intends to enter the pharmaceutical space, diversifying its business model beyond its traditional custom synthesis and specialty chemicals operations.
- How much of Bliss GVS Pharma is being acquired?
- The board has approved the acquisition of up to 74.20% of the equity share capital of the company.
- What is the financial value of the deal?
- The company has not disclosed the financial consideration for the acquisition in its regulatory filing.
- Is this a done deal?
- No, the acquisition is subject to customary regulatory approvals.
Story so far
All notes on ANURAS →- Today · 7:33 PM IST Anupam Rasayan buys 74.20% stake in Bliss GVS Pharma
- today Anupam Rasayan revenue grew 65% in FY26 as margins dropped to 23%
- 1d ago Anupam Rasayan buys control of Bliss GVS Pharma for ₹2,200 crore